At the time of writing, BioAge Labs Inc [BIOA] stock is trading at $4.27, up 7.02%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BIOA shares have gain 7.29% over the last week, with a monthly amount glided 2.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley downgraded its rating to Underweight on December 10, 2024, and dropped its price target to $5. On December 09, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $7 on the stock. Citigroup downgraded its rating to a Neutral and decreased its price target to $7 on December 09, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $40 as its price target on October 21, 2024. Jefferies started tracking with a Buy rating for this stock on October 21, 2024, and assigned it a price target of $42. In a note dated October 21, 2024, Citigroup initiated an Buy rating and provided a target price of $45 on this stock.
For the past year, the stock price of BioAge Labs Inc fluctuated between $2.88 and $26.62. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. BioAge Labs Inc [NASDAQ: BIOA] shares were valued at $4.27 at the most recent close of the market. An investor can expect a potential return of 40.52% based on the average BIOA price forecast.
Analyzing the BIOA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.38 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that BioAge Labs Inc [NASDAQ:BIOA] has a current ratio of 13.68. In addition, the Quick Ratio stands at 13.68 and the Cash Ratio stands at 10.85. Considering the valuation of this stock, the price to sales ratio is 105.57, the price to book ratio is 0.49.
Transactions by insiders
Recent insider trading involved Barton Shane, Principal Accounting Officer, that happened on Sep 27 ’24 when 2632.0 shares were purchased. Director, Pande Vijay Satyanand completed a deal on Oct 01 ’24 to buy 0.13 million shares. Meanwhile, Director Pande Vijay Satyanand bought 67096.0 shares on Oct 02 ’24.
